[go: up one dir, main page]

BRPI0009956A - composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e betametasona, e, uso da mesma - Google Patents

composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e betametasona, e, uso da mesma

Info

Publication number
BRPI0009956A
BRPI0009956A BRPI0009956A BRPI0009956A BRPI0009956A BR PI0009956 A BRPI0009956 A BR PI0009956A BR PI0009956 A BRPI0009956 A BR PI0009956A BR PI0009956 A BRPI0009956 A BR PI0009956A BR PI0009956 A BRPI0009956 A BR PI0009956A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
calcipotriol
betamethasone
dermatological
aqueous pharmaceutical
Prior art date
Application number
BRPI0009956A
Other languages
English (en)
Inventor
Erik Didriksen
Gert Hoy
Original Assignee
Leo Pharm Prod Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8094933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0009956(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Pharm Prod Ltd filed Critical Leo Pharm Prod Ltd
Priority to BR122012030847-1A priority Critical patent/BR122012030847B1/pt
Publication of BRPI0009956A publication Critical patent/BRPI0009956A/pt
Publication of BRPI0009956B1 publication Critical patent/BRPI0009956B1/pt
Publication of BRPI0009956B8 publication Critical patent/BRPI0009956B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"composição farmacêutica para uso dermatológico, uso de uma composição, e, método de tratamento de psoríase e doenças de pele relacionadas". a presente invenção refere-se a uma composição farmacêutica para uso dermatológico, referida composição compreendendo um primeiro componente a farmacologicamente ativo consistindo de pelo menos uma vitamina d ou análogo de vitamina d, e um segundo componente b farmacologicamente ativo consistindo de pelo menos um corticosteróide.
BRPI0009956 1999-04-23 2000-01-27 Composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e betametasona, e, uso da mesma BRPI0009956B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122012030847-1A BR122012030847B1 (pt) 1999-04-23 2000-01-27 Composição farmacêutica não aquosa para uso dermatológico, e, uso da mesma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900561 1999-04-23
PCT/DK2000/000033 WO2000064450A1 (en) 1999-04-23 2000-01-27 Pharmaceutical composition

Publications (3)

Publication Number Publication Date
BRPI0009956A true BRPI0009956A (pt) 2002-01-08
BRPI0009956B1 BRPI0009956B1 (pt) 2014-11-11
BRPI0009956B8 BRPI0009956B8 (pt) 2021-07-06

Family

ID=8094933

Family Applications (3)

Application Number Title Priority Date Filing Date
BR122012030847-1A BR122012030847B1 (pt) 1999-04-23 2000-01-27 Composição farmacêutica não aquosa para uso dermatológico, e, uso da mesma
BR122012030846A BR122012030846B8 (pt) 1999-04-23 2000-01-27 composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e pelo menos um corticoesteróide, e, uso da mesma
BRPI0009956 BRPI0009956B8 (pt) 1999-04-23 2000-01-27 Composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e betametasona, e, uso da mesma

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR122012030847-1A BR122012030847B1 (pt) 1999-04-23 2000-01-27 Composição farmacêutica não aquosa para uso dermatológico, e, uso da mesma
BR122012030846A BR122012030846B8 (pt) 1999-04-23 2000-01-27 composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e pelo menos um corticoesteróide, e, uso da mesma

Country Status (30)

Country Link
US (1) US6753013B1 (pt)
EP (5) EP2450043B1 (pt)
JP (4) JP4426729B2 (pt)
KR (1) KR100694526B1 (pt)
CN (1) CN1173703C (pt)
AU (1) AU774600B2 (pt)
BG (1) BG65115B1 (pt)
BR (3) BR122012030847B1 (pt)
CA (1) CA2370565C (pt)
CY (5) CY1113967T1 (pt)
CZ (1) CZ303142B6 (pt)
DK (5) DK2455083T3 (pt)
ES (5) ES2432691T3 (pt)
HK (1) HK1045650B (pt)
HR (1) HRP20010779B1 (pt)
HU (1) HU230045B1 (pt)
IL (2) IL145983A0 (pt)
IS (1) IS6120A (pt)
LT (2) LT3146969T (pt)
ME (1) ME00298B (pt)
MX (1) MXPA01010676A (pt)
NO (1) NO329486B1 (pt)
NZ (1) NZ515142A (pt)
PL (1) PL199123B1 (pt)
PT (5) PT1178808E (pt)
RS (1) RS52182B (pt)
RU (1) RU2238734C2 (pt)
SI (3) SI2915534T1 (pt)
SK (1) SK287653B6 (pt)
WO (1) WO2000064450A1 (pt)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
DK2455083T3 (da) 1999-04-23 2013-09-30 Leo Pharma As Farmaceutisk sammensætning til dermal anvendelse omfattende calcipotriol og betamethason til behandling af psoriasis
WO2006120681A2 (en) * 2005-05-10 2006-11-16 Dermipsor Ltd. Compositions and methods for skin care
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
EP1330468B1 (en) * 2000-09-18 2007-08-01 Applied Research Systems ARS Holding N.V. Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids
AU9163701A (en) 2000-10-27 2002-05-06 Leo Pharma As Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid
US20090143328A1 (en) * 2001-08-13 2009-06-04 Mcdonald George Method of Treating Cancer by Administration of Topical Active Corticosteroids
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20080138296A1 (en) * 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
JP2006505583A (ja) 2002-10-25 2006-02-16 フォーミックス エルティーディー． 化粧剤および医薬用フォーム
US20080031907A1 (en) * 2002-10-25 2008-02-07 Foamix Ltd. Cosmetic and pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) * 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
EP1458678A1 (en) * 2002-11-18 2004-09-22 Teva Pharmaceutical Industries Limited A crystallization method for purification of calcipotriene
EP1854466A1 (en) * 2002-12-17 2007-11-14 Galderma Research & Development, S.N.C. Pharmaceutical composition comprising a combination of calcitriol and clobetasol propionate
DE60316724T2 (de) * 2002-12-17 2008-07-17 Galderma S.A. Pharmazeutische zusammensetzung enthaltend calcitriol und clobetasolpropionat
FR2848454B1 (fr) * 2002-12-17 2007-03-30 Galderma Res & Dev Composition pharmaceutique comprenant une association de calcitriol et d'un corticosteroide
JP2004359585A (ja) * 2003-06-03 2004-12-24 Medorekkusu:Kk 被膜形成型の副腎皮質ステロイド薬含有外用製剤
FR2856301B1 (fr) 2003-06-23 2007-08-03 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
AR045241A1 (es) * 2003-08-12 2005-10-19 Novartis Consumer Health Sa Composicion topica que comprende terbinafina e hidrocortisona
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
US20070299041A1 (en) * 2004-05-26 2007-12-27 Cedars-Sinai Medical Center Induction of innate immunity by vitamin d3 and its analogs
EP1758589A1 (en) * 2004-06-17 2007-03-07 Galderma S.A. Composition for the treatment of psoriasis comprising a silicone agent, a corticosteroid and vitamin d or a derivative thereof
CA2567684A1 (en) * 2004-06-17 2005-12-29 Galderma S.A. Composition in the form of a spray comprising a combination of clobetasol propionate and calcitriol, an alcohol phase and an oily phase
FR2871695B1 (fr) 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un agent silicone et deux principes actifs solubilises
FR2871697B1 (fr) * 2004-06-17 2007-06-29 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile
FR2871698B1 (fr) * 2004-06-17 2008-07-04 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques et une phase huileuse
FR2871693B1 (fr) * 2004-06-17 2006-08-25 Galderma Sa Utilisation d'une composition pharmaceutique comprenant du calcitriol et du propionate de clobetasol pour le traitement du psoriasis
FR2871694B1 (fr) * 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises
FR2871700B1 (fr) * 2004-06-17 2006-11-17 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, et une phase huileuse
FR2871696B1 (fr) * 2004-06-17 2006-11-10 Galderma Sa Composition topique pour le traitement du psoriasis
BRPI0511389A (pt) * 2004-06-17 2007-12-04 Galderma Sa composição e seu uso
FR2871699A1 (fr) * 2004-06-17 2005-12-23 Galderma Sa Composition de type emulsion inverse contenant du calcitrol et du 17-propionate de clobetasol, et ses utilisations en cosmetiques et en dermatologie
JP2006131544A (ja) * 2004-11-05 2006-05-25 Medorekkusu:Kk 皮膚疾患治療用外用剤
DE602005021245D1 (de) * 2004-11-22 2010-06-24 Wisconsin Alumni Res Found 2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen
WO2006111426A1 (en) * 2005-04-19 2006-10-26 Galderma S.A. Composition of film-forming solution type, comprising vitamin d or a derivative thereof and a corticosteroid, and use thereof in dermatology
FR2884419B1 (fr) * 2005-04-19 2007-06-22 Galderma Sa Composition de type solution filmogene comprenant de la vitamine d ou un de ses derives et un corticosteroide, et son utilisation en dermatologie
US9173835B2 (en) * 2005-05-10 2015-11-03 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
JP5612263B2 (ja) * 2005-06-01 2014-10-22 スティーフェル リサーチ オーストラリア ピーティーワイ リミテッド ビタミン製剤
US20080152596A1 (en) * 2005-07-19 2008-06-26 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
JP5204088B2 (ja) 2006-03-17 2013-06-05 レオ ファーマ アクティーゼルスカブ 医薬中間体の異性化
ATE444071T1 (de) * 2006-08-17 2009-10-15 Klever Mode S L Pharmazeutische zusammensetzungen zur behandlung von hauterkrankungen
CN101505725A (zh) * 2006-08-29 2009-08-12 特瓦制药工业有限公司 包含含维生素D的化合物和皮质类固醇化合物的具有低pH相容性的稳定的药理学活性组合物
JP2010504994A (ja) * 2006-09-28 2010-02-18 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−（２０ｓ，２５ｓ）−１９，２７−ジノル−（２２ｅ）−ビタミンｄ類縁体
US7741314B2 (en) * 2006-09-28 2010-06-22 Wisconsin Alumni Research Foundation 2-Methylene-(20R,25S)-19,27-Dinor-(22E)-Vitamin D Analogs
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
FR2909284B1 (fr) * 2006-11-30 2012-09-21 Galderma Sa Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
ES2272198B1 (es) * 2006-12-28 2008-06-01 Laboratorios Viñas S.A. Procedimiento para la obtencion de hidrato de calcipotriol.
EP1970049A1 (en) * 2007-03-15 2008-09-17 Drug Delivery Solutions Limited Polyaphron topical composition with vitamin D and corticosteroid
EP1970048A1 (en) * 2007-03-15 2008-09-17 Drug Delivery Solutions Limited Polyaphron topical composition with vitamin D
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
HU227970B1 (en) 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) * 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US9220701B2 (en) * 2008-10-03 2015-12-29 Nexmed Holdings, Inc. Stabilized composition for treating psoriasis
RU2396081C1 (ru) * 2008-12-29 2010-08-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения дерматозов, поддающихся глюкокортикостероидной терапии, и способ ее получения
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2010129062A1 (en) * 2009-05-07 2010-11-11 Jason Carbol Pharmaceutical composition including a corticosteroid and a vitamin d analog having improved stability
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US20110053898A1 (en) * 2009-08-26 2011-03-03 Glenmark Generics Ltd Topical composition comprising vitamin d analogue and corticosteroids
LT2482822T (lt) 2009-10-01 2018-09-10 Adare Pharmaceuticals, Inc. Geriamosios kortikosteroidų kompozicijos
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
CN102770121B (zh) * 2009-12-22 2014-10-15 利奥制药有限公司 包含溶剂混合物和维生素d衍生物或类似物的药物组合物
ES2529506T3 (es) 2010-06-11 2015-02-20 Leo Pharma A/S Una composición farmacéutica para aspersión que comprende un análogo de la vitamina D y un corticosteroide
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
HRP20191711T1 (hr) 2011-03-14 2019-12-13 Drug Delivery Solutions Ltd Oftalmološki pripravak
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
CN103110648A (zh) * 2013-01-25 2013-05-22 江苏圣宝罗药业有限公司 钙泊三醇倍他米松软膏及其制备方法
CN105102438B (zh) 2013-01-29 2019-04-30 埃维克辛公司 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CN104666312B (zh) * 2015-02-12 2017-11-07 重庆华邦制药有限公司 含有卡泊三醇和二丙酸倍他米松的制剂
MA41818A (fr) * 2015-03-27 2018-01-30 Leo Pharma As Timbre à micro-aiguilles pour administration d'un principe actif à la peau
TW201636025A (zh) * 2015-04-15 2016-10-16 Maruho Kk 皮膚用之醫藥組成物
KR101641372B1 (ko) * 2015-05-08 2016-07-20 (주)동구바이오제약 안정성과 피부투과율이 향상된 약학 조성물
CN107157917B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种用于治疗银屑病的软膏的制备方法
CN107157920B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种包含维生素d或其衍生物的半固体制剂的制备方法
CN107157918B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种用于银屑病治疗的半固体制剂的制备方法
CN107157919B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种用于治疗银屑病的半固体制剂的制备方法
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
WO2019072353A1 (en) * 2017-10-11 2019-04-18 Elmasry Mohamed Zakria Ahmed Ali TOPICAL PHARMACEUTICAL PREPARATION OF BETAMETHASONE, CALCIPOTRIOL AND ROSE OIL FOR THE TREATMENT OF PSORIASIS
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
FR3083701B1 (fr) 2018-07-13 2020-08-14 Gifrer Barbezat Liniment oleo-alcalin
JP7350985B2 (ja) * 2020-03-19 2023-09-26 シオノギヘルスケア株式会社 ベタメタゾン吉草酸エステル含有組成物
US12005067B2 (en) * 2020-12-04 2024-06-11 Incyte Corporation JAK inhibitor with a vitamin D analog for treatment of skin diseases
CN115177586A (zh) * 2022-08-31 2022-10-14 江苏知原药业股份有限公司 一种卡泊三醇组合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB892127A (en) * 1958-03-03 1962-03-21 Merck & Co Inc Therapeutic preparations comprising steroids and vitamin d
DK116528A (pt) * 1966-09-30
US4083974A (en) 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
JPS59139315A (ja) * 1983-01-31 1984-08-10 Taisho Pharmaceut Co Ltd クリ−ム剤
US4569935A (en) * 1983-03-17 1986-02-11 University Of Tennessee Research Corp. Topical treatment of psoriasis with imidazole antibiotics
US4610978A (en) * 1983-03-22 1986-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same
JP2522962B2 (ja) * 1986-09-19 1996-08-07 中外製薬株式会社 乾癬治療剤
US4847071A (en) 1987-10-22 1989-07-11 The Procter & Gamble Company Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent
GB8821129D0 (en) * 1988-09-09 1988-10-12 Unilever Plc Cosmetic composition
GB8904154D0 (en) * 1989-02-23 1989-04-05 Leo Pharm Prod Ltd Chemical compounds
GB9004544D0 (en) 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
US5087620A (en) * 1990-05-17 1992-02-11 Bristol-Myers Squibb Co. Controlled dermal penetration enhancement using imidazoles
US5185150A (en) 1990-08-24 1993-02-09 Wisconsin Alumni Research Fdn. Cosmetic compositions containing 19-nor-vitamin D compounds
IL99368A (en) 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
GB9226860D0 (en) * 1992-12-23 1993-02-17 Leo Pharm Prod Ltd Novel treatment
USRE39706E1 (en) * 1993-01-15 2007-06-26 Leo Pharma A/S Crystalline form of a vitamin D analogue
GB9314400D0 (en) * 1993-07-12 1993-08-25 Leo Pharm Prod Ltd Produktionsaktieselskab) chemical compounds
JPH07173053A (ja) * 1993-12-20 1995-07-11 Otsuka Pharmaceut Co Ltd 抗微生物剤
JP3506474B2 (ja) * 1994-01-07 2004-03-15 帝人株式会社 安定性の向上した乾癬治療剤
TW460296B (en) * 1994-09-01 2001-10-21 Janssen Pharmaceutica Nv Topical ketoconazole emulsion compositions without sodium sulfite
US5840925A (en) * 1995-06-29 1998-11-24 Hauser, Inc. Trioxane dimer compounds having antiproliferative and antitumor activities
WO1997013518A1 (en) * 1995-10-10 1997-04-17 Marilyn Strube Treatment of pruritus with vitamin d and analogs thereof
FR2740042B1 (fr) * 1995-10-23 1997-11-14 Oreal Support, et composition contenant ce support et un actif cosmetique ou dermatologique stabilise
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
JPH1067757A (ja) * 1996-06-21 1998-03-10 Ss Pharmaceut Co Ltd トリアゾール誘導体またはその塩
JPH10139669A (ja) * 1996-11-05 1998-05-26 Teijin Ltd 脂漏性角化症治療剤
ATE312087T1 (de) * 1997-05-16 2005-12-15 Woman & Infants Hospital Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen
WO1998051664A1 (en) * 1997-05-16 1998-11-19 Women & Infants Hospital 3-epi vitamin d2 compounds and uses thereof
US6372233B1 (en) * 1997-12-09 2002-04-16 Chugai Seiyaku Kabushiki Kaisha Lotions containing vitamin D3 derivatives
KR20010032892A (ko) * 1997-12-09 2001-04-25 나가야마 오사무 비타민 ｄ３유도체를 함유하는 크림제
JPH11188054A (ja) * 1997-12-25 1999-07-13 Lion Corp 皮膚外用部材
JPH11246329A (ja) * 1998-02-27 1999-09-14 Shiseido Co Ltd 皮膚外用剤
BR9904847B1 (pt) * 1998-03-04 2010-07-13 loção em emulsão de vitamina d3 ativa.
US5886038A (en) * 1998-03-24 1999-03-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
US5990100A (en) 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
DK2455083T3 (da) 1999-04-23 2013-09-30 Leo Pharma As Farmaceutisk sammensætning til dermal anvendelse omfattende calcipotriol og betamethason til behandling af psoriasis

Also Published As

Publication number Publication date
NO20015175L (no) 2001-10-23
DK3146969T3 (en) 2018-08-27
RU2238734C2 (ru) 2004-10-27
JP5886999B2 (ja) 2016-03-16
SI2915534T1 (sl) 2018-10-30
DK1178808T4 (da) 2019-09-02
LT3146969T (lt) 2018-09-25
NO329486B1 (no) 2010-10-25
ES2432691T3 (es) 2013-12-04
JP2008297309A (ja) 2008-12-11
HRP20010779B1 (hr) 2011-02-28
AU2278300A (en) 2000-11-10
YU75701A (sh) 2005-07-19
CY1114420T1 (el) 2016-08-31
IL145983A (en) 2006-08-20
EP2455083B1 (en) 2013-09-18
EP2915534A1 (en) 2015-09-09
LT2915534T (lt) 2018-06-25
BRPI0009956B1 (pt) 2014-11-11
MEP39108A (en) 2011-02-10
CA2370565C (en) 2008-11-25
ES2671785T3 (es) 2018-06-08
AU774600B2 (en) 2004-07-01
HU230045B1 (hu) 2015-06-29
NZ515142A (en) 2004-01-30
PT2455083E (pt) 2013-10-09
NO20015175D0 (no) 2001-10-23
PT3146969T (pt) 2018-10-18
EP3146969A1 (en) 2017-03-29
DK2450043T3 (en) 2016-09-12
HK1045650B (zh) 2005-04-08
EP2915534B1 (en) 2018-03-14
BR122012030846B1 (pt) 2021-04-27
CZ20013739A3 (cs) 2002-06-12
SI3146969T1 (en) 2018-08-31
CY1118206T1 (el) 2017-06-28
US6753013B1 (en) 2004-06-22
DK2915534T3 (en) 2018-06-14
BR122012030846B8 (pt) 2021-05-25
CY1113967T1 (el) 2016-07-27
BRPI0009956B8 (pt) 2021-07-06
ES2674563T3 (es) 2018-07-02
ES2388425T3 (es) 2012-10-15
JP2002542293A (ja) 2002-12-10
IS6120A (is) 2001-10-22
PT2915534T (pt) 2018-06-20
CA2370565A1 (en) 2000-11-02
EP1178808B1 (en) 2012-05-30
PT2450043T (pt) 2016-10-12
JP4426729B2 (ja) 2010-03-03
HUP0200879A2 (en) 2002-08-28
DK1178808T3 (da) 2012-07-30
EP2450043A1 (en) 2012-05-09
JP2013075923A (ja) 2013-04-25
EP2450043B1 (en) 2016-08-17
EP3146969B1 (en) 2018-06-20
JP5721926B2 (ja) 2015-05-20
SK287653B6 (sk) 2011-05-06
WO2000064450A1 (en) 2000-11-02
CN1351499A (zh) 2002-05-29
BG65115B1 (bg) 2007-03-30
PL199123B1 (pl) 2008-08-29
CN1173703C (zh) 2004-11-03
KR20010110803A (ko) 2001-12-13
CY1120313T1 (el) 2019-07-10
ME00298B (me) 2011-05-10
RS52182B (sr) 2012-10-31
ES2388425T5 (es) 2020-02-12
EP2455083A1 (en) 2012-05-23
BR122012030847B1 (pt) 2021-07-06
HUP0200879A3 (en) 2004-04-28
KR100694526B1 (ko) 2007-03-13
SK15182001A3 (sk) 2002-06-04
HRP20010779A2 (en) 2002-12-31
EP1178808A1 (en) 2002-02-13
CZ303142B6 (cs) 2012-05-02
ES2602450T3 (es) 2017-02-21
DK2455083T3 (da) 2013-09-30
HK1045650A1 (en) 2002-12-06
PT1178808E (pt) 2012-08-16
SI1178808T1 (sl) 2012-10-30
CY1120659T1 (el) 2019-12-11
MXPA01010676A (es) 2003-08-20
PL351387A1 (en) 2003-04-07
BG106030A (en) 2002-05-31
JP2015155451A (ja) 2015-08-27
IL145983A0 (en) 2002-07-25
EP1178808B2 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
BRPI0009956A (pt) composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e betametasona, e, uso da mesma
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
PT1079806E (pt) Preparacoes para a aplicacao de anti-inflamatorios, especialmente, agentes anti-septicos e/ou agentes de promocao da cura de feridas, no tracto respiratorio superior e/ou no ouvido
BR0211673A (pt) Terapia dermal utilizando derivados de fosfato de agentes de transferência de elétrons
BR0311939A (pt) composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico
ES2063073T3 (es) Derivados de arilmetilenilo conocidos y nuevos seleccionados de tiazolidinonas, imidazolidinonas y oxazolidinonas utiles como agentes antialergicos y agentes antiinflamatorios.
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR9910066A (pt) Composição farmacêutica fluida que permite a liberação controlada de pelo menos uma substância ativa, processo de fabricação de uma composição farmacêutica, e, utilização de uma composição
BR0114927A (pt) Composição de gel farmacêutica substancialmente não aquosa para aplicação na pele, e, uso da composição
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
BR9712610A (pt) Composições farmacêutica e liquida, uso de aciclovir ou de um derivado do mesmo farmaceuticamente aceitável, processo para preparação de uma composição, e, disportivo de aplicação tópica.
BR0314308A (pt) Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto
ATE323473T1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
BR0003897A (pt) Aditivo para aumento da resistência à água de formulações cosméticas ou dermatológicas e seus usos
BR0313388A (pt) Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase
EP0382066A3 (de) Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
DE69932939D1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/11/2014, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/01/00, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 23A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2707 DE 22/11/2022 POR TER SIDO INDEVIDA.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 11/11/2024